entertainment -WSS

entertainment

author：entertainment 2025-09-27 16:35:43 - browse：667

A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT — Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

leisure time

WSS

Medicare wants to send $9 billion to 340B hospitals

Sweden knocks USA out of World Cup in penalty kicks

Home health providers sue Medicare over payment cuts

Judge agrees to delay next hearing in Trump classified documents case

Paxlovid rebound happens. Why and to whom are still a mystery

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

focus

entertainment

hotspot

The high cost of giving birth even with insurance

Pandemic and All Hazards Preparedness Act needs lean update

The cancer drug shortage isn’t new — and neither are the solutions

Trump used to be more articulate. What could explain the change?

Novavax promises a turnaround & Lilly roils the obesity market

ACA's risk program benefits Blue Cross Blue Shield insurers

The high cost of giving birth even with insurance

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

BioMarin wins approval for gene therapy to treat hemophilia A

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

hotspot

ACA's risk program benefits Blue Cross Blue Shield insurers

Recent heat wave in the Mediterranean caused by climate change: Study

Swim instructor mom warns parents not to buy blue swimsuits for kids

Election results set back Medicaid expansion plans

Slovenia has suffered its worst

Swim instructor mom warns parents not to buy blue swimsuits for kids

leisure time

hotspot

leisure time

focus